Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation

被引：5

作者：

Shah, Nirali N. ^{[1
]}

Azzi, Jacques ^{[2
]}

Cooper, Brenda W. ^{[3
]}

Deol, Abhinav ^{[4
]}

DiPersio, John ^{[5
]}

Koura, Divya ^{[6
]}

McClune, Brian ^{[7
]}

Muffly, Lori S. ^{[8
]}

Mushtaq, Muhammad Umair ^{[9
]}

Narayan, Rupa ^{[10
]}

Suh, Hyung Chan ^{[11
]}

Yanik, Gregory ^{[12
]}

Nath, Sritama ^{[13
]}

Whangbo, Jennifer ^{[13
]}

Koehne, Guenther ^{[14
]}

机构：

[1] Natl Inst Hlth, Pediat Oncol Branch, Bethesda, MD USA

[2] Icahn Sch Med Mt Sinai, Div Hematol & Med Oncol Cellular Therapy & Bone M, Tisch Canc Inst, New York, NY USA

[3] Univ Hosp Seidman Canc Ctr, Cleveland, OH USA

[4] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA

[5] Washington Univ, Dept Internal Med, Div Oncol, St Louis, MO USA

[6] UCSD Moores Canc Ctr, La Jolla, CA USA

[7] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[8] Stanford Univ, Sch Med, Div Blood & Marrow Transplantat & Cellular Therap, Stanford, CA USA

[9] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Westwood, KS USA

[10] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA USA

[11] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[12] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[13] Vor Biopharma, Cambridge, MA USA

[14] Miami Canc Inst, Baptist Hlth South Florida, Miami, FL USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180990

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia
Pan, Jing
Zuo, Shiyu
Li, Chuo
Ling, Zhuojun
Xu, Jinlong
Duan, Jiajia
Wang, Zelin
Wu, Tong
Feng, Xiaoming
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[22] In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia
Minagawa, Kentaro
Jamil, Muhammad O.
Al-Obaidi, Mustafa
Pereboeva, Larisa
Salzman, Donna
Erba, Harry P.
Lamb, Lawrence S.
Bhatia, Ravi
Mineishi, Shin
Di Stasi, Antonio
PLOS ONE, 2016, 11 (12):
[23] FUNCTIONAL EVALUATION OF ANTI-CD33 CAR-T CELLS GENERATED FROM HEALTHY DONOR AND ACUTE MYELOID LEUKEMIA PATIENTS
Calvino, C.
Ceballos, C.
Inoges, S.
Lopez-Diaz, de Cerio A.
San Martin-Uriz, P.
Calleja-Cervantes, M. E.
Rodriguez-Marquez, P.
Martin-Mallo, A.
Rodriguez-Diaz, S.
Martinez-Turrillas, R.
Jauregui, P.
Rifon, J.
Rodriguez-Otero, P.
Alfonso, A.
Lasarte, J. J.
Viguria, M. C.
Redondo, M.
Rodriguez-Madoz, J. R.
Prosper, F.
HAEMATOLOGICA, 2021, 106 (10) : 59 - 59
[24] DRAMATIC REGRESSION OF CHRONIC LYMPHOCYTIC LEUKEMIA IN THE FIRST PATIENT TREATED WITH DONOR-DERIVED GENETICALLY-ENGINEERED ANTI-CD 19-CHIMERIC-ANTIGEN-RECEPTOR-EXPRESSING T CELLS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kochenderfer, J. N.
Dudley, M. E.
Maric, I
Feldman, S. A.
Salit, R.
Hardy, N. M.
Layton, P.
Blacklock-Schuver, B.
Wilder, J.
Devillier, L.
Gress, R. E.
Morgan, R. A.
Rosenberg, S. A.
Bishop, M. R.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S158 - S158
[25] CD33 Directed Chimeric Antigen Receptor T Cell Therapy As a Novel Preparative Regimen Prior to Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia
Kenderian, Saad S.
Ruella, Marco
Shestova, Olga
Klichinsky, Michael
Scholler, John
Song, Decheng
Porter, David L.
Carroll, Martin
June, Carl H.
Gill, Saar
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S25 - S26
[26] Role of Donor-Derived CD19.CAR-T Cells in Treating Patients That Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation
Zhang, Cheng
Gao, Lei
Liu, Yao
Gao, Li
Kong, Pei-Yan
Liu, Jun
Huang, Ruihao
Ma, Ying-Ying
Zeng, Defu
Xiong, Qing-Hui
Mei, Wei-Ling
Liu, Jia
Jiang, Peng-Fei
Ye, Xun
Han, De-Ping
Cao, Wei
Zhang, Xi
BLOOD, 2019, 134
[27] DONOR-DERIVED LYMPHOID ANTIGEN-DIRECTED CAR-T CELLS FOR RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA IN CHILDREN AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: REPORT OF 17 CASES
Molostova, Olga
Shelikhova, Larisa
Khismatullina, Rimma
Lyudovskikh, Evelina
Abugova, Yuliya
Pershin, Dmitriy
Klimentova, Maria
Shipitsina, Irina
Malakhova, Ekaterina
Fadeeva, Maria
Kulakovskaya, Alena
Khachatryan, Lili
Vedmedskaya, Viktoria
Novichkova, Galina
Maschan, Alexei
Maschan, Michael
BONE MARROW TRANSPLANTATION, 2024, 59 : 223 - 223
[28] DONOR-DERIVED CAR-T CELLS FOR THE TREATMENT OF RELAPSED ACUTE B-LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Deng, Lei
Yu, Xiaolin
Song, Xiaocheng
Guan, Rui
Shao, Yan
Li, Wenjun
Zhou, Fang
BONE MARROW TRANSPLANTATION, 2024, 59 : 47 - 48
[29] Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
马润芝
China Medical Abstracts(Internal Medicine), 2021, 38 (04) : 228 - 229
[30] Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
Simona Lapusan
Maria B. Vidriales
Xavier Thomas
Stephane de Botton
Anne Vekhoff
Ruoping Tang
Charles Dumontet
Rodica Morariu-Zamfir
John M. Lambert
Marie-Laure Ozoux
Philippe Poncelet
Jesus F. San Miguel
Ollivier Legrand
Daniel J. DeAngelo
Francis J. Giles
Jean-Pierre Marie
Investigational New Drugs, 2012, 30 : 1121 - 1131

← 1 2 3 4 5 →